Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 106

Similar articles for PubMed (Select 23921786)

1.

Can serum angiogenin be used to improve the diagnostic performance in prostate cancer screening?

Pina F, Botelho F, Lopes T, Lopes I, Figueiredo G, Portugal R, Ferro A, Cruz F, Barros H, Lunet N.

Eur J Cancer Prev. 2014 May;23(3):166-72. doi: 10.1097/CEJ.0b013e3283647453.

PMID:
23921786
2.

Determination of the percentage of free prostate-specific antigen helps to avoid unnecessary biopsies in men with normal rectal examinations and total prostate-specific antigen of 4-10 ng/ml.

Martínez-Piñeiro L, Tabernero A, Contreras T, Madero R, Lozano D, López-Tello J, Alonso-Dorrego JM, Picazo ML, González Gancedo P, Martínez-Piñeiro JA, de La Peña JJ.

Eur Urol. 2000 Mar;37(3):289-96.

PMID:
10720854
3.

Clinical usefulness of free PSA in early detection of prostate cancer.

Luboldt HJ, Swoboda A, Börgermann C, Fornara P, Rübben H; Early Detection Project Group of the German Society of Urology.

Onkologie. 2001 Feb;24(1):33-7.

PMID:
11441278
4.

Diagnostic performance of malignant prostatic cells detection in blood for early detection of prostate cancer: comparison to prostatic biopsy.

Murray NP, Reyes E, Tapia P, Orellana N, Dueñas R, Fuentealba C, Badinez L.

Arch Esp Urol. 2011 Dec;64(10):961-71. English, Spanish.

PMID:
22228894
5.

Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter.

Horninger W, Cheli CD, Babaian RJ, Fritsche HA, Lepor H, Taneja SS, Childs S, Stamey TA, Sokoll LJ, Chan DW, Brawer MK, Partin AW, Bartsch G.

Urology. 2002 Oct;60(4 Suppl 1):31-5.

PMID:
12384160
6.

The Prostate Health Index in predicting initial prostate biopsy outcomes in Asian men with prostate-specific antigen levels of 4-10 ng/mL.

Ng CF, Chiu PK, Lam NY, Lam HC, Lee KW, Hou SS.

Int Urol Nephrol. 2014 Apr;46(4):711-7. doi: 10.1007/s11255-013-0582-0. Epub 2013 Oct 18.

PMID:
24136184
7.

Serum proteomic profiling can discriminate prostate cancer from benign prostates in men with total prostate specific antigen levels between 2.5 and 15.0 ng/ml.

Ornstein DK, Rayford W, Fusaro VA, Conrads TP, Ross SJ, Hitt BA, Wiggins WW, Veenstra TD, Liotta LA, Petricoin EF 3rd.

J Urol. 2004 Oct;172(4 Pt 1):1302-5.

PMID:
15371828
8.

Multiparametric magnetic resonance imaging of the prostate can improve the predictive value of the urinary prostate cancer antigen 3 test in patients with elevated prostate-specific antigen levels and a previous negative biopsy.

Sciarra A, Panebianco V, Cattarino S, Busetto GM, De Berardinis E, Ciccariello M, Gentile V, Salciccia S.

BJU Int. 2012 Dec;110(11):1661-5. doi: 10.1111/j.1464-410X.2012.11146.x. Epub 2012 May 4.

PMID:
22564540
9.

Zinc α2-glycoprotein as a potential novel urine biomarker for the early diagnosis of prostate cancer.

Katafigiotis I, Tyritzis SI, Stravodimos KG, Alamanis C, Pavlakis K, Vlahou A, Makridakis M, Katafigioti A, Garbis SD, Constantinides CA.

BJU Int. 2012 Dec;110(11 Pt B):E688-93. doi: 10.1111/j.1464-410X.2012.11501.x. Epub 2012 Sep 28.

PMID:
23020913
10.

[Parameters to improve the specificity of the prostate-specific antigen. Early detection of prostate cancer].

Börgermann C, Kliner S, Swoboda A, Luboldt HJ, Rübben H.

Urologe A. 2011 Sep;50(9):1095-100. doi: 10.1007/s00120-011-2577-8. German.

PMID:
21567277
11.

Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: a multicentric European study.

Lazzeri M, Haese A, de la Taille A, Palou Redorta J, McNicholas T, Lughezzani G, Scattoni V, Bini V, Freschi M, Sussman A, Ghaleh B, Le Corvoisier P, Alberola Bou J, Esquena Fernández S, Graefen M, Guazzoni G.

Eur Urol. 2013 Jun;63(6):986-94. doi: 10.1016/j.eururo.2013.01.011. Epub 2013 Jan 24.

PMID:
23375961
12.

Prediction of prostate cancer in extended-field biopsies of the prostate.

Winkler MH, Kulinskaya E, Gillatt DA.

BJU Int. 2004 Mar;93(4):516-21.

PMID:
15008721
13.

Clinical utility of the prostate cancer gene 3 (PCA3) urine assay in Japanese men undergoing prostate biopsy.

Ochiai A, Okihara K, Kamoi K, Oikawa T, Shimazui T, Murayama S, Tomita K, Umekawa T, Uemura H, Miki T.

BJU Int. 2013 May;111(6):928-33. doi: 10.1111/j.1464-410X.2012.11683.x. Epub 2013 Jan 18.

PMID:
23331404
14.

Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.

Guazzoni G, Nava L, Lazzeri M, Scattoni V, Lughezzani G, Maccagnano C, Dorigatti F, Ceriotti F, Pontillo M, Bini V, Freschi M, Montorsi F, Rigatti P.

Eur Urol. 2011 Aug;60(2):214-22. doi: 10.1016/j.eururo.2011.03.052. Epub 2011 Apr 5.

PMID:
21482022
15.

[The incidence of the variability of the free PSA/total PSA ratio on the early diagnosis of prostate cancer].

de La Taille A, Houlgatte A, Houdelette P, Berlizot P, Fournier R, Ricordel I.

Prog Urol. 1997 Jun;7(3):455-63. Review. French.

PMID:
9273075
16.

Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves.

Catalona WJ, Richie JP, deKernion JB, Ahmann FR, Ratliff TL, Dalkin BL, Kavoussi LR, MacFarlane MT, Southwick PC.

J Urol. 1994 Dec;152(6 Pt 1):2031-6.

PMID:
7525994
17.

Insulin-like growth factor-1 and insulin-like growth factor binding protein-3 for prostate cancer detection in patients undergoing prostate biopsy.

Ismail A H, Pollak M, Behlouli H, Tanguay S, Begin LR, Aprikian AG.

J Urol. 2002 Dec;168(6):2426-30.

PMID:
12441932
18.
19.

A novel algorithm for the prediction of prostate cancer in clinically suspected patients.

Gallotta A, Ziglioli F, Ferretti S, Maestroni U, Moretti M, Aloe R, Gnocchi C, Di Palo M, Fassina G.

Cancer Biomark. 2013;13(4):227-34. doi: 10.3233/CBM-130357.

PMID:
24240583
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk